ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
119.298,67
0,25%
S&P 500
5.842,91
0,11%
US Dollar vs BRL
6,0559
-0,64%
Bitcoin
96.634,47
2,25%
Brent Oil
79,70
-0,72%
As Melhores Corretoras Online
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NYSE
  6. Biohaven Ltd (BHVN)

  7. Biohaven Ltd (BHVN) Notícias

BHVN

Biohaven (BHVN)

Biohaven Ltd
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NYSE:BHVN
DataHoraFonteTítuloCódigoCompanhia
13/01/202513:16Edgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
13/01/202513:15PR Newswire (US)Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation PoNYSE:BHVNBiohaven Ltd
12/01/202522:04GlobeNewswire Inc.Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC ProgramsNYSE:BHVNBiohaven Ltd
07/01/202519:54PR Newswire (US)Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNYSE:BHVNBiohaven Ltd
16/12/202409:30PR Newswire (US)Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program UpdatesNYSE:BHVNBiohaven Ltd
06/12/202409:30PR Newswire (US)Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual MeetingNYSE:BHVNBiohaven Ltd
25/11/202409:30PR Newswire (US)Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and ObesityNYSE:BHVNBiohaven Ltd
12/11/202418:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:BHVNBiohaven Ltd
12/11/202418:05PR Newswire (US)Biohaven Reports Third Quarter 2024 Financial Results and Recent Business DevelopmentsNYSE:BHVNBiohaven Ltd
02/10/202417:05PR Newswire (US)Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesNYSE:BHVNBiohaven Ltd
01/10/202417:06Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:BHVNBiohaven Ltd
01/10/202407:00PR Newswire (US)Biohaven Announces Pricing of $250 Million Public Offering of Common SharesNYSE:BHVNBiohaven Ltd
30/09/202417:05PR Newswire (US)Biohaven Announces Proposed Public Offering of Common SharesNYSE:BHVNBiohaven Ltd
30/09/202408:30PR Newswire (US)Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of MigraineNYSE:BHVNBiohaven Ltd
24/09/202407:15IH Market NewsVisa Faces Monopoly Lawsuit; Meta Introduces Celebrity Voices for Chatbot; Stellantis on the Hunt for New CEONYSE:BHVNBiohaven Ltd
23/09/202408:30PR Newswire (US)Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)NYSE:BHVNBiohaven Ltd
20/09/202420:09PR Newswire (US)Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar AtaxiaNYSE:BHVNBiohaven Ltd
16/08/202417:31Edgar (US Regulatory)Form 424B7 - Prospectus [Rule 424(b)(7)]NYSE:BHVNBiohaven Ltd
08/08/202417:05PR Newswire (US)Biohaven Reports Second Quarter 2024 Financial Results and Recent Business DevelopmentsNYSE:BHVNBiohaven Ltd
29/05/202408:30PR Newswire (US)Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D DayNYSE:BHVNBiohaven Ltd
29/05/202408:15PR Newswire (US)Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial TumorsNYSE:BHVNBiohaven Ltd
09/05/202417:16Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNYSE:BHVNBiohaven Ltd
09/05/202417:05PR Newswire (US)Biohaven Reports First Quarter 2024 Financial Results and Recent Business DevelopmentsNYSE:BHVNBiohaven Ltd
13/04/202410:00PR Newswire (US)Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business UpdatesNYSE:BHVNBiohaven Ltd
29/02/202418:05PR Newswire (US)Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business DevelopmentsNYSE:BHVNBiohaven Ltd
08/01/202409:30PR Newswire (US)Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and OncoloNYSE:BHVNBiohaven Ltd
02/01/202409:00PR Newswire (US)Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNYSE:BHVNBiohaven Ltd
01/12/202318:30PR Newswire (US)Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual MeetingNYSE:BHVNBiohaven Ltd
14/11/202318:05PR Newswire (US)Biohaven Reports Third Quarter 2023 Financial Results and Recent Business DevelopmentsNYSE:BHVNBiohaven Ltd
16/10/202308:00PR Newswire (US)Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®NYSE:BHVNBiohaven Ltd
 Apresentando as notícias mais relevantes sobre:NYSE:BHVN

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
PRIO3
PETRORIO ON
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
FICT3
Fictor Alimentos ON
BOV
BHIA3
Grupo Casas Bahia ON
BOV
RCSL4
RECRUSUL PN
BOV
PMAM3
PARANAPANEMA ON
BOV
RAIZ4
Raizen S.A PN
BOV
TELB4
TELEBRAS PN
BOV
HOOT4
HOTEIS OTHON PN
BOV
GOLL4
GOL PN
BOV
FNAM11
Fundo Invest Amazonia Fi...
BOV
COGN3
COGNA ON
BOV
RNEW4
RENOVA PN
BOV
JHSF3
JHSF PART ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados